Searched over 200M research papers
7 papers analyzed
These studies suggest that HDL has antiviral and atheroprotective properties, while LDL is associated with atherogenicity and oxidative stress.
20 papers analyzed
High-density lipoprotein (HDL) and low-density lipoprotein (LDL) are two types of lipoproteins that play crucial roles in the body's lipid metabolism. While both are essential for transporting cholesterol, they have distinct functions and implications for health.
HDL is known for its protective effects against cardiovascular diseases. It exhibits antioxidant and anti-inflammatory properties, which are crucial for preventing the oxidation of LDL particles—a key step in the development of atherosclerosis. HDL functionality, particularly its cholesterol efflux capacity (CEC), is a significant determinant of its protective role. CEC refers to HDL's ability to remove cholesterol from macrophages, which is inversely associated with carotid intima-media thickness and coronary artery disease (CAD).
HDL consists of two major subfractions: HDL2 and HDL3. HDL2 is more closely associated with reduced risk factors for atherosclerosis, such as lower body mass index (BMI), fasting glucose, and insulin levels, compared to HDL3. This suggests that HDL2 may offer better protection against atherosclerosis.
Interestingly, HDL also exhibits antiviral properties. Native HDL has been shown to have potent antiviral effects against SARS-CoV-2, the virus responsible for COVID-19. However, this antiviral activity is compromised when HDL undergoes glycation, a process common in diabetic patients, which may explain their increased susceptibility to COVID-19.
LDL is often referred to as "bad cholesterol" due to its role in atherogenesis. The oxidative modification of LDL particles is a critical factor in their atherogenicity. Small, dense LDL particles are particularly prone to oxidation and are strongly associated with increased cardiovascular risk . These particles are more likely to penetrate the arterial wall and contribute to plaque formation.
The atherogenic potential of LDL is not uniform across all its subfractions. Small, dense LDL particles are more atherogenic compared to larger, buoyant LDL particles. This is because they have a higher propensity for oxidation and are more closely associated with insulin resistance and glucose intolerance. Additionally, non-HDL cholesterol, which includes all atherogenic lipoproteins, is a better marker for cardiovascular risk compared to LDL cholesterol alone.
Recent research has explored the use of LDL and HDL as nanocarriers for targeted drug delivery in cancer therapy. LDLs are primarily taken up by cancer cells, while HDLs are preferentially taken up by macrophages. This selective uptake can be leveraged to deliver chemotherapeutic agents directly to their target cells, enhancing treatment efficacy and reducing side effects.
Both HDL and LDL properties are influenced by various cardiovascular risk factors. For instance, dyslipidemia and male sex are predominantly linked to HDL dysfunctionality, while diabetes and advanced age are associated with LDL atherogenicity. This highlights the importance of considering both HDL functionality and LDL atherogenic traits in assessing cardiovascular risk.
HDL and LDL play distinct yet interconnected roles in lipid metabolism and cardiovascular health. While HDL is generally protective due to its antioxidant, anti-inflammatory, and cholesterol efflux capabilities, LDL is atherogenic, especially in its small, dense form. Understanding the nuanced roles of these lipoproteins can aid in developing targeted therapies for cardiovascular diseases and other conditions.
Most relevant research papers on this topic